Bortezomib, the first-in-class proteasome inhibitor, has become one of the standard
treatments in multiple myeloma. The agent is thought to exert its antimyeloma effects through …

Background. The efficacy of plasma cell targeted therapies for antibody-mediated rejection
(AMR) has not been defined in detail. The purpose of this study was to compare early and …

Although acute renal graft rejection rate has declined in the last years, and because an
adequate therapy can improve graft outcome, its therapy remains as one of the most …

Klotho Regulates Epithelial-to-Mesenchymal Transition In Vitro via Wnt/β-Catenin Pathway
and Attenuates Chronic Allograft Dysfunction in a Rat Renal Transplant Model - PMC Back to …

The current evidence clearly points towards donor specific alloantibody as a major cause of
allograft loss. In order to mitigate allograft loss due to antibodies, treating the source of …

Roberti I, Geffner S, Vyas S. Successful rescue of refractory acute antibody‐mediated renal
allograft rejection with splenectomy–A case report. Pediatr Transplantation 2012: 16: E49 …

Abstract aAMR in renal allografts is uncommon and remains a challenge as it is often
refractory to treatment modalities. Aggressive therapy is essential to reverse the rejection as …

Аннотация Реципиенты почки могут иметь предсуществующие антидонорские
антитела или вырабатывать de novo анти-HLA-или не-анти-HLA-антитела после …

Kidney transplant recipients may have pre-transplant alloantibodies or develop de novo anti-
HLA and non-HLA antibodies after transplantation. Although these antibodies may be donor …

Background: Bortezomib has been used to treat antibody-mediated rejection (AMR) that
usually develops after kidney transplantation (KT). Although it has been used in various …